Introduction
Bifidobacterium is one of the most widely used probiotic bacteria [1] [2] [3] [4] . It is believed that Bifidobacterium species are important in maintaining intestinal health because they contribute to beneficial microbiota in the intestinal tract, including the prevention of intestinal colonization by pathogenic bacteria [5, 6] . Thus, the beneficial effects of Bifidobacterium intake in the form of probiotics have been focused on in previous studies [7, 8] .
Bifidobacterium bifidum BGN4 was isolated from healthy breast-fed infants as a probiotic strain that contributed to intestinal health. Several health-associated characteristics from in vivo and in vitro experiments substantiate the fact that B. bifidum BGN4 can inhibit cancer and boost the host immune system. For instance, the anticarcinogenic polysaccharide isolated from B. bifidum BGN4 inhibited the growth of cancer cell lines [9] . Furthermore, B. bifidum BGN4 is reported to have a potent adhering activity with respect to Caco-2 cells [10] . In vivo intervention studies suggest that B. bifidum BGN4 administration alleviates allergic reactions elicited by ovalbumin in a mouse model and in infants at high risk of allergy during the first year of life [11, 12] .
B. bifidum BGN4 is now being used to produce various commercial probiotic products. The consumption of the product results in the improvement of intestinal microbiota, such as increase of the viable number of Bifidobacterium and reduced number of Escherichia coli, Bacteroides, and Clostridium in the fecal sample during the intake period [13] . However, to establish a specific monitoring system for B. bifidum BGN4 in clinical fecal samples from a subject fed B. bifidum BGN4, B. bifidum BGN4-specific PCR primers are required. For this reason, we developed B. bifidum BGN4-specific PCR primer sets that will be used to verify the quality and presence of this strain in probiotic products and fecal samples for both laboratory and industrial applications.
Strain-specific identification was carried out in previous studies by specific culture practices, and then DNA fingerprinting or enzyme-linked immunosorbent assay (ELISA) using monoclonal antibodies [14] [15] [16] . However, these methods are time-consuming and need a practiced hand to perform them. PCR-based identification methods using strain-specific primers are simple, rapid, and accurate methods. These methods have been established for several industrially valuable probiotic strains [17] [18] [19] . To verify the efficacy of probiotics in clinical tests, it is necessary to detect specific probiotics in clinical fecal samples or dairy products using strain-specific primer sets; however, few studies have identified strain-specific PCR primer sequences [20, 21] .
Ribosomal RNA genes and the intergenic region-based detection assay, such as PCR, have been designed to detect bacteria at the species level [22] [23] [24] . However, the 16S rRNA gene sequence is not a suitable PCR primer target for strain level identification because of the highly conserved character of this gene. Therefore, we designed strainspecific primers based on the complete genome sequence of B. bifidum BGN4, which we determined in a previous study [25; GenBank Accession No. CP001361]. The whole genome of B. bifidum BGN4 was compared with other deposited genomes of Bifidobacterium strains to discover a B. bifidum BGN4-specific region. The specific region sequences were used to develop PCR primers.
In this study, we developed B. bifidum BGN4-specific primer sets and evaluated the B. bifidum BGN4 detection limit using these primers sets to confirm their application in fecal samples and dairy products.
Materials and Methods

Bacterial Strains and DNA Preparation
The various Bifidobacterium strains and other lactic acid bacteria used in this study are listed in Table 1 . These strains were freshly cultured in Lactobacilli MRS broth (MRS; BD Biosciences, USA) supplemented with 0.05% L-cysteine·HCl (Sigma-Aldrich, USA) at 37°C for 15 h. Then, 500 µl of the sample mixture was used for DNA isolation. DNA was extracted from the cell pellet using the DNeasy Blood and Tissue kit (Qiagen, Germany) according to the manufacturer's instructions and stored at -20°C until use.
Oligonucleotide Primers
Bioneer Co. (Korea) synthesized all oligonucleotide primers used in this study. MegaBLAST was used to align genome sequences of various Bifidobacterium strains to detect B. bifidum BGN4-specific regions. Four PCR primer sets were designed using the sequences in those regions. The primer sequences are shown in Table 2 along with their corresponding GenBank accession numbers and predicted product sizes. The primer pairs were designed to have a similar melting temperature (T m ) and to yield products that differed from each other by >100 bp, which could be resolved by 3% low-melting-point agarose gel (Sigma-Aldrich, USA) electrophoresis ( Table 2 ). The BLAST program was used to ensure that the proposed primers were complementary with the target strain, but not with other strains.
Amplification of Multiplex PCR and Analysis of its Products
Our multiplex PCR amplification system using 50 µl of reaction mixture was as follows: The PCR mix was composed of 33.9 µl deionized distilled water, 5 µl 2× GC buffer II (Takara, Japan), 5 µl dNTP mixture (2.5 mM, Takara), 0.5 µl each primer (100 µM), 2.5 U LA Taq (Takara), and 5 µl template DNA. PCR amplification was performed using the GenAmp9700 thermal cycler (Applied Biosystem, USA). Target amplification was initiated at 95°C for 3 min, followed by 30 cycles of 3-step cycles of denaturation at 95°C for 3 min, annealing at 72°C for 90 sec, extension at 72°C for 1 min, and a final extension of 72°C for 10 min. Amplified PCR products were analyzed by gel electrophoresis on a 3% low-melting-point agarose gel containing the Loading Star (Dynebio, Korea) and visualized by ultraviolet light using ethidium bromide staining.
Sensitivity and Specificity Assays
The sensitivity of the multiplex PCR was tested using a serial dilution of B. bifidum BGN4 prepared from overnight cultures in MRS. The bacteria were serially diluted (2.8 × 10 7 , 2.8 × 10 6 , 2.8 × 10 5 , 2.8 × 10 4 , 2.8 × 10 3 , 2.8 × 10 2 , 2.8 × 10 1 , 2.8 × 10 0 CFU/ml) in phosphate-buffered saline (PBS). DNA was isolated from 500 µl of each dilution and subsequently tested using the multiplex PCR assay.
The multiplex PCR specificity was determined by examining the ability to detect and distinguish B. bifidum BGN4 among 82 strains of Bifidobacterium, and 14 non-Bifidobacterium strains.
Fecal Sample Collection and DNA Extraction
Seoul National University's Institutional Animal Care and Use Committee approved all animal care procedures prior to experiment initiation. Two-week-old C57BL/6 mice, which are the general animal model for the study of probiotic effect of lactic acid bacteria [26] , were purchased from Central Laboratory Animal Inc. (Korea) and divided into two groups of five mice. Mice were housed in a standard animal laboratory with a 12:12 h light:dark cycle and allowed free access to water.
B. bifidum BGN4, obtained from Research Institute Bifido Co. Ltd. (Korea), was mixed with the mouse AIN-93G diet. Mice in the B. bifidum BGN4 group were administered B. bifidum BGN4 bacterial powder. Mice in the sham group received no bacteria. As a positive control, B. bifidum BGN4-treated mice were fed 0.2% of lyophilized B. bifidum BGN4 (1.0 × 10 9 CFU/g) via a diet pellet. Mice were fed the experimental bacterial powders for 2 weeks.
The fecal samples were collected on days 1, 3, 7, 10, and 14 after feeding. The total genomic DNA from each fecal sample was extracted using the QIAamp DNA stool mini kit (Qiagen) according to the manufacturer's instructions.
Probiotic Products and DNA Extraction
In this study, four commercially available probiotic products collected from various retail stores in Korea, were analyzed. In addition to B. bifidum BGN4 products, the choices of other products were also based on the number of different bacterial groups claimed on the product label. As shown in Table 3 , the products investigated contained 3-6 bacterial strains. One gram of commercial probiotic product was resuspended in 1 ml of PBS to remove saccharides. Then, pellets were collected by centrifugation at 4,000 ×g for 30 min. Bacterial DNAs were extracted using the DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer's instructions.
Results
Establishment of the Multiplex Primer Set for B. bifidum BGN4 Identification
Novel multiplex PCR primer sets for probiotic Bifidobacterium bifidum BGN4 identification were constructed from molecular chaperone sequences (GenBank Accession No. BBB_1207; primer 6-forward and primer 10-reverse), hypothetical proteins (GenBank Accession No. BBB_1208; primer 7-forward), and putative secreted transglycosylase genes (GenBank Accession No. BBB_1209; primer 4 pair) through comparison of genome sequences of Bifidobacterium strains. Other primer sequences, like primer 6-reverse, primer 7-reverse, and primer 10-forward, were located in non-functional protein sequences of B. bifidum BGN4 ( Table 2 ). The B. bifidum BGN4-specific primer sets produced four amplicons at each expected size of 362, 540, 752, and 847 bp (Fig. 1) . They clearly discriminated B. bifidum BGN4 from other lactic acid bacteria because the strain-specific amplicon of B. bifidum BGN4 revealed four amplicons.
Specificity of the B. bifidum BGN4 Primer Sets
To verify whether the primers were available for strainspecific identification of B. bifidum BGN4, the PCR assay was performed with 96 lactic acid bacteria, including 82 Bifidobacterium and 14 non-Bifidobacterium strains. The primers produced the four expected amplicons only from B. bifidum BGN4. They did not interfere with each other and the multiplex PCR correctly detected and discriminated B. bifidum BGN4 from other tested bifidobacteria and LAB. No other strains produced four amplicons simultaneously, although B. bifidum KCTC3440 and Bifidobacterium sp. RD10 produced three amplicons in the PCR product (Table 4) . Furthermore, 14 non-Bifidobacterium strains did not produce any amplicons. Thus, using our technique, B. bifidum BGN4 could be distinguished from other Bifidobacterium species.
Detection Limits of the Multiplex PCR Fig. 2 shows the sensitivity of the B. bifidum BGN4-specific PCR method using 10-fold serially diluted B. bifidum BGN4 DNA templates. The PCR was performed with genomic DNA of B. bifidum BGN4 extracted from different bacterial concentrations of 2.8 × 10 1 CFU/ml and, therefore, the detection limit for this multiplex PCR assay in pure culture was determined as 2.8 × 10 1 CFU/ml.
Application of the Multiplex PCR for Identifying B. bifidum BGN4 from Probiotic Products
The primer sets we established were applied to identify B. bifidum BGN4 from commercial probiotic products. Five probiotic products claiming to contain several probiotic strains, including B. bifidum BGN4, were tested (Table 3) . Amplicons corresponding to B. bifidum BGN4 were not found in the other probiotic products (Fig. 3A) . Our multiplex PCR system did not detect amplicons corresponding to B. bifidum BGN4 in the probiotic products containing different B. bifidum strains (products III and V, lanes 3 and 5, Fig. 3A ). Only the product claiming to contain B. bifidum BGN4 (Lane 1, Fig. 3A) produced B. bifidum BGN4-specific amplicon.
Multiplex PCR Application for Identifying B. bifidum BGN4 from Fecal Matter In order to estimate whether the multiplex PCR system is a reliable tool for the detection of B. bifidum BGN4 from various samples, we tried to detect B. bifidum BGN4 from mouse feces. Fresh murine fecal samples were collected at 1, 3, 7, 10, and 14 days after diet feeding as described in the Materials and Methods section. Among these, B. bifidum BGN4 was detected from all fecal samples in the B. bifidum BGN4 group (Figs. 3B-3F lanes 1-5) by B. bifidum BGN4-specific multiplex PCR assay. Amplicons corresponding to 
B. bifidum BGN4 were not found in the control group (Figs. 3B-3F lanes 6-10).
Discussion
Although conventional microbiological methods such as biochemical and genotypical methods for identifying Bifidobacterium strains are reliable, these methods need several days to complete. PCR is generally considered to be a time-saving and sensitive method for the detection of bacterial species. In previous studies, PCR-based strainspecific identification using strain-specific primers was reported for several probiotics and fecal samples [18, 19] . This technique is a valuable means to identify strains in commercialized products and to monitor the population of probiotics in humans or animals in clinical studies.
Therapeutic benefits of Bifidobacterium bifidum BGN4 application have been shown in different randomized, controlled clinical trials [12] . Kim et al. [12] clearly demonstrate that B. bifidum BGN4-specific PCR assays are necessary for effective and accurate identification of this strain, not only from pure cultures, but also from fecal samples after oral administration. This study satisfied these needs (Tables 1 and 3) .
Four PCR primer pairs for B. bifidum BGN4 (primer 4, primer 6, primer 7, and primer 10 pair) were designed based on B. bifidum BGN4-specific sequences, including partial molecular chaperone, hypothetical protein, and putative secreted transglycosylase. Among them, the primer 4 pair was not selective enough for the other tested Bifidobacterium strains (14.8% positive). In contrast to primer 4 pair, the other three primer pairs (primer 6, primer 7, and primer 10 pair) were better suited for the specific detection of B. bifidum BGN4. Nevertheless, B. bifidum BGN4-specific primers clearly discriminated BGN4 from other B. bifidum strains, such as B. bifidum KCTC3202, B. bifidum KCTC3418, B. bifidum KCTC3281, B. bifidum KCTC3357, B. bifidum KCTC3440, and B. bifidum ATTC15521, because the four amplicons of B. bifidum BGN4 were not detected simultaneously with other B. bifidum strains.
In B. bifidum BGN4 from pure culture, the sensitivity of the B. bifidum BGN4-specific PCR assay for direct detection was tested. Although B. bifidum BGN4 at 2.8 × 10 1 CFU/ml showed very weak bands in the detection limit assay, the four amplicons were successfully amplified at this concentration. Therefore, the detection limit was determined to be 2.8 × 10 1 CFU/ml. This sensitivity is comparable to other Bifidobacterium-specific PCR assays reported [27] .
In conclusion, for BGN4 strain-specific identification, we created a specific PCR system targeting the B. bifidum BGN4-specific sequence, based on partial molecular chaperone, hypothetical protein, and putative secreted transglycosylase gene sequences. The system developed in this study is a valuable tool to monitor the B. bifidum BGN4 content of probiotic products and in human specimens, where the accuracy and specificity of the identification is of the utmost importance. The results in this study suggest that the next step is to combine this method with real-time PCR and propidium monoazide to identify the viable cells of BGN4 in complex microbiota compositions, as suggested for other probiotic strains [17] . 
